|Articles|July 1, 1999

July 1999
Volume 5
Issue 7

The Cost of Alzheimer's Disease in Managed Care: A Cross-Sectional Study

Author(s)Joel Leon, PhD, Peter Neumann, ScD

Download PDF: The Cost of Alzheimer's Disease in Managed Care: A Cross-Sectional Study

Articles in this issue

almost 27 years ago

Article

Hospital Expenditures and Utilization: The Impact of HMOs

almost 27 years ago

Article

Efficacy and Cost Effectiveness of Lansoprazole Versus Omeprazole in Maintenance Treatment of Symptomatic Gastroesophageal Reflux Disease

almost 27 years ago

Article

Payor Cost Savings with Endometrial Ablation Therapy

almost 27 years ago

Article

The Food and Drug Administration and Atrial Defibrillation Devices

almost 27 years ago

Article

Benign Prostatic Hyperplasia: New Concepts for the Millennium

almost 27 years ago

Article

Breast Cancer Prevention: The Role of Antiestrogens

almost 27 years ago

Article

The Impact of HMOs on Hospital Use and Cost? A Matter of Interpretation

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

The Cost of Alzheimer's Disease in Managed Care: A Cross-Sectional Study

Articles in this issue

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

Trending on AJMC

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year

GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis

Oral Orforglipron Added to Basal Insulin Cuts HbA1c in Type 2 Diabetes

Childhood Influenza Vaccine Rates Decreased From 2017 to 2023